Clinigen Announces Shaun Chilton to Take Over as Chief Executive Officer

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services group, has been notified by Peter George that he intends to step down as Chief Executive Officer (‘CEO’) on 11 November 2016. He will continue as a non executive director.
Shaun Chilton, who has been Deputy CEO since July 2015 and before that
Chief Operating Officer for over three years, will become CEO on that
date.
Separately Robin Sibson, who has served as non executive director since
2015 and before that as the Group’s Chief Financial Officer, has
notified the Board that he intends to retire from the Board at the AGM
in November.
Peter Allen, Chairman said:
“Peter has done a tremendous job developing and growing Clinigen over
the last six years.
“He built the business from a small private company to its current
position as a leading global pharmaceutical products and services
business with a market capitalisation of some £800m. He led the IPO four
years ago and the two substantial transformational acquisitions over the
last 18 months.
“The Board looks forward to working with Shaun. He has held a number
of senior roles in Clinigen over the last four years and been closely
involved in its development. He has the international industry
knowledge, expertise and leadership skills to take this business forward.
“I would also like to thank Robin for his continued contribution to
the business since he became a non executive director just over a year
ago.”
Peter George, CEO, Clinigen said:
“It has been a pleasure and privilege to create and lead Clinigen
over the last six years with the IPO, strong organic growth and the two
recent transformational acquisitions being the highlights. I would like
to thank all of the Group’s employees around the world – we have been
only able to create this substantial business thanks to their hard work
and commitment.
“I have worked closely with Shaun over the years and I would like to
thank him for his invaluable contribution. I look forward to supporting
him as he takes the business to the next stage in its development.”
Shaun Chilton, CEO-designate said:
“I am delighted to have the opportunity to lead Clinigen. We have
been building the Group’s infrastructure, capabilities, IP and
geographical footprint over the last four years, creating a unique
business model with a top quality management team.
“Our focus now is to drive sustainable growth by capitalising on our
market leading positions in clinical trial services and unlicensed
medicines and continuing to expand our portfolio of specialty
pharmaceuticals.”
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services
company with a unique combination of businesses focused on providing
access to medicines. Its mission is to deliver the right medicine to the
right patient at the right time.
The Group consists of five synergistic businesses focused in three areas
of global medicine supply; clinical trial, unlicensed and licensed
medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and
supplying unlicensed medicines to hospital pharmacists and physicians
for patients with a high unmet need, through three of its divisions: Idis
Managed Access runs early access programs for innovative new
medicines. Idis Global Access and Link Healthcare work
directly with healthcare professionals to enable compliant access to
unlicensed medicines on a global basis and niche essential licensed and
generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital commercial
products.
For more information, please visit www.clinigengroup.com